ANI Pharmaceuticals Inc (ANIP) Q3 2026 Earnings Call Highlights: Strong Revenue Growth Offset ...
ANI Pharmaceuticals Inc (ANIP) posted 28% revenue growth and raised EBITDA guidance, but revised Cortrophin outlook and a $560 million rare disease acquisition dominated the Q3 2026 earnings call. Related Stocks: ANIP ,